AXSM
Axsome Therapeutics Inc

11,685
Mkt Cap
$6.34B
Volume
163,544.00
52W High
$139.13
52W Low
$75.56
PE Ratio
-25.06
AXSM Fundamentals
Price
$129.60
Prev Close
$127.06
Open
$127.61
50D MA
$120.53
Beta
0.64
Avg. Volume
547,157.14
EPS (Annual)
-$5.99
P/B
86.62
Rev/Employee
$564,704.25
Loading...
Loading...
News
all
press releases
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. If...
Business Wire·5h ago
News Placeholder
More News
News Placeholder
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Zacks·24d ago
News Placeholder
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Zacks·2mo ago
News Placeholder
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Zacks·3mo ago
News Placeholder
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·3mo ago
News Placeholder
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
Zacks·3mo ago

Latest AXSM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.